艾迪注射液联合TC化疗方案治疗子宫内膜癌患者的效果

Effects of Aidi injection combined with TC chemotherapy in treatment of patients with endometrial cancer

目的:观察艾迪注射液联合卡铂^(+)紫杉醇(TC)化疗方案治疗子宫内膜癌(EC)患者的效果。方法:回顾性收集2021年6月至2023年6月该院收治的68例EC患者的临床资料,按治疗方案不同将其分为对照组与观察组各34例。对照组采用TC化疗方案治疗,观察组在对照组基础上联合艾迪注射液治疗。比较两组疾病控制率,治疗前后T细胞亚群指标(CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+))水平、疾病相关指标[血清高半胱氨酸蛋白61(Cyr61)、内脂素(Visfatin)]水平,以及不良反应发生率。结果:观察组疾病控制率为94.12%,高于对照组的76.47%,差异有统计学意义(P<0.05);治疗后,两组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)水平均低于治疗前,但观察组高于对照组,差异有统计学意义(P<0.05);治疗后两组Cyr61、Visfatin水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);观察组骨髓抑制、脱发、肝肾功能异常、消化道反应等不良反应发生率与对照组比较,差异均无统计学意义(P>0.05)。结论:艾迪注射液联合TC化疗方案治疗EC患者可提高疾病控制率和T细胞亚群指标水平,以及降低疾病相关指标水平的效果优于单纯TC化疗方案治疗。

Objective:To observe effects of Aidi injection combined with Carboplatin and paclitaxel(TC)chemotherapy in treatment of patients with endometrial carcinoma(EC).Methods:The clinical data of 68 patients with EC admitted to the hospital from June 2021 to June 2023 were retrospectively collected.According to different treatment schemes,they were divided into control group and observation group,34 cases in each group.The control group was treated with TC chemotherapy regimen,while the observation group was treated with Aidi injection on the basis of that of the control group.The disease control rate,the levels of T cell subsets(CD3^(+),CD4^(+),CD4^(+)/CD8^(+)),disease-related indicators[serum homocysteine protein 61(Cyr61),visfatin],and the incidence of adverse reactions were compared between the two groups before and after the treatment.Results:The disease control rate of the observation group was 94.12%,which was higher than 76.47%of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of CD3^(+),^(+)CD4 and CD4^(+)/CD8^(+)in the two groups were lower than those before the treatment,but those in the observation group were higher than those in the control group,and the differences were statistically significant(P<0.05).After treatment,the levels of Cyr61 and visfatin in the two groups were lower than those before the treatment,and the observation group was lower than the control group,and the differences were statistically significant(P<0.05).The incidence of adverse reactions such as bone marrow suppression,alopecia,liver and kidney dysfunction,and gastrointestinal reactions in the observation group was not significantly different from that in the control group(P>0.05).Conclusions:Aidi injection combined with TC chemotherapy can improve the disease control rate and the T cell subset levels in the patients with EC,and reduce the levels of disease-related indicators.Moreover,it is superior to simple TC chemotherapy.